Skip to content

Curcumin in patients cancer cachexic anorexia

A double-blind placebo-controlled randomized phase IIa study: evaluating the effect of curcumin for treatment of cancer anorexia cachexia syndrome in solid cancer patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220521003
Enrollment
60
Registered
2022-05-21
Start date
2020-10-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with cancer anorexic cachexia. Advanced solid cancers, cancer anorexic cachexia.

Interventions

800 mg per capsule, oral supplement Curcumin, 1 capsule oral twice daily.,oral capsule 1 capsule oral twice daily.
Active Comparator Dietary Supplement,Placebo Comparator Dietary Supplement

Sponsors

Phramongkutklao Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients had to be at least 18 years of age ECOG PS 0 or 2 Adequate hematologic hepatic and renal function

Exclusion criteria

Exclusion criteria: Patients with an unstable medical condition or undercurrent illness, including active infections requiring treatment with systemic antibiotics, unstable coagulation disorders, high risk of clinical bleeding, history of hypersensitivity to curcumin, and obstructive jaundice were excluded. In addition, pregnant and breastfeeding women were excluded.

Design outcomes

Primary

MeasureTime frame
Body compositions (body fat mass, skeletal muscle mass) At the beginning of the study, and 8 weeks after randomization. Kilograms

Secondary

MeasureTime frame
Body weight At the beginning of study, and at 8 weeks after randomization. Kilograms

Countries

Thailand

Contacts

Public ContactNaiyarat Prasongsook

Phramongkutklao Hospital

naiyarat_p@yahoo.co.th0973654159

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026